Photo from wikipedia
A tumor-penetrating bicyclic peptide that delivers a toxic payload may have finally unlocked the therapeutic potential of targeting EphA2. According to phase I trial data, BT5528 yielded clinical responses in… Click to show full abstract
A tumor-penetrating bicyclic peptide that delivers a toxic payload may have finally unlocked the therapeutic potential of targeting EphA2. According to phase I trial data, BT5528 yielded clinical responses in three patients with ovarian and urothelial cancers-without any of the toxicity issues that have plagued other EphA2-directed therapeutic candidates.
Keywords:
makes targeting;
peptide makes;
bicyclic peptide;
targeting epha2;
epha2 possible
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!